CIZZLE BIOTECHNOLOGY HOLDINGS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.5 GBX | -1.64% |
|
-9.09% | -23.08% |
| Apr. 30 | EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down | AN |
| Apr. 30 | Cizzle Biotechnology Holdings Plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 7.09M 9.07M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 | Net income 2023 | -1M -1.28M | EV / Sales 2022 | - |
| Net cash position 2022 | 478K 611K | Net cash position 2023 | 1.56M 1.99M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.63
x | P/E ratio 2023 |
-4.04
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.88% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.64% | ||
| 1 week | -9.09% | ||
| Current month | -10.45% | ||
| 1 month | -15.49% | ||
| 3 months | -31.82% | ||
| 6 months | -34.78% | ||
| Current year | -23.08% |
1 week
1.49
1.70
1 month
1.491.85
Current year
1.493.38
1 year
1.493.38
3 years
1.307.50
5 years
1.3013.00
10 years
1.3013.00
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dawn Coverley
BRD | Director/Board Member | 59 | 21-05-13 |
Nigel Lee
DFI | Director of Finance/CFO | 63 | 21-05-13 |
John Treacy
BRD | Director/Board Member | 42 | 19-01-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-13 | 1.5 | -1.64% | 252 222 |
| 24-06-12 | 1.525 | 0.00% | 262,610 |
| 24-06-11 | 1.525 | -1.61% | 618,494 |
| 24-06-10 | 1.55 | -6.06% | 2,735,060 |
| 24-06-07 | 1.65 | 0.00% | 80,643 |
Delayed Quote London S.E., June 13, 2024 at 05:03 am EDT
More quotes
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.08% | 7.76M | |
| +48.54% | 56.61B | |
| +36.84% | 39.25B | |
| -6.02% | 39.62B | |
| -6.90% | 28.28B | |
| +12.97% | 26.44B | |
| -16.91% | 20.12B | |
| +31.71% | 12.48B | |
| +28.18% | 12.51B | |
| +0.38% | 12.2B |
- Stock Market
- Equities
- PSL Stock
